Moderna Shares Plummet After Slashing Revenue Forecast—Blames UK Vaccine Delivery Delays
:max_bytes(150000):strip_icc()/GettyImages-2227553133-e6d21cdee8954e4dab5adb3907d89158.jpg)
Another day, another biotech stumble—Moderna just handed investors a fresh reason to sweat.
What happened?
The mRNA pioneer’s stock nosedived after admitting revenue won’t meet expectations. Blame? A classic case of ‘supply chain issues’—this time, delayed UK vaccine shipments.
Why it matters:
Wall Street hates surprises, especially when they involve nine-figure guidance cuts. Moderna’s now stuck explaining how a logistics hiccup torpedoes their financials—while analysts whisper about demand erosion.
The kicker:
This comes just as rival Pfizer ramps up its own mRNA pipeline. Coincidence? Or proof that even pandemic darlings aren’t immune to gravity—or competent competitors?
*Cue hedge funds shorting the dip while retail bagholders ‘buy the opportunity.’*
